{"title":"Eli Lilly Joins ImmunoGen’s List of Big Pharma Collaborators","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i1.1648","DOIUrl":null,"url":null,"abstract":"Eli Lilly has gained rights to use ImmunoGen’s maytansinoid targeted antibody payload (TAP) technology to develop a specified number of antibody-drug conjugates for the potential treatment of cancer. ImmunoGen will receive US$20 M upfront and could receive up to US$200 M in milestone payments for each licence taken as well as royalties on sales of any resulting products. With this deal, Eli Lilly has joined ImmunoGen’s list of TAP partners that includes Amgen, Bayer Healthcare, Roche, Novartis and Sanofi.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i1.1648","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Eli Lilly has gained rights to use ImmunoGen’s maytansinoid targeted antibody payload (TAP) technology to develop a specified number of antibody-drug conjugates for the potential treatment of cancer. ImmunoGen will receive US$20 M upfront and could receive up to US$200 M in milestone payments for each licence taken as well as royalties on sales of any resulting products. With this deal, Eli Lilly has joined ImmunoGen’s list of TAP partners that includes Amgen, Bayer Healthcare, Roche, Novartis and Sanofi.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
